Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Essential Thrombocythemia Enrolled in the MOST Study
Abdulraheem Yacoub, Roger Lyons, Srdan Verstovsek, Ryan Shao, David Tin Chu, Apurv Agrawal, Smitha Sivaraman, Philomena Colucci, Dilan Paranagama, John Mascarenhas, Abdulraheem Yacoub, Roger Lyons, Srdan Verstovsek, Ryan Shao, David Tin Chu, Apurv Agrawal, Smitha Sivaraman, Philomena Colucci, Dilan Paranagama, John Mascarenhas
Abstract
Few data exist regarding the disease and clinical characteristics of patients with essential thrombocythemia (ET) in the United States. The ongoing, multicenter, noninterventional, prospective, Myelofibrosis and Essential Thrombocythemia Observational STudy (MOST) was designed to collect data pertaining to the demographics, clinical management, and patient-reported outcomes in patients with myelofibrosis or ET in the United States (NCT02953704). This analysis examines the clinical characteristics of patients with clinical diagnoses of high-risk or low-risk ET receiving ET-directed therapy at enrollment. At data cutoff (June 17, 2019), 1207 of 1234 enrolled patients were eligible for this analysis (median age, 70 years; 65% female; 88% white); 917 patients (76%) had mutation testing results available. The median time from ET diagnosis to study enrollment was 4.2 years. The majority of patients (87%) had high-risk ET. Of 333 patients with a history of thrombotic events, 247 had at least 1 event classified as arterial and/or venous. Platelet count was above normal range in 54% of patients. Hypertension (56%) was the most common comorbidity. At enrollment, the majority of patients (low-risk ET, 94%; high-risk ET, 79%) were receiving ET-directed monotherapy. Additional prospective analyses from MOST will help to identify areas of unmet need.
Keywords: Demographics; Myeloproliferative neoplasm; Observational study; Real-world; Treatment patterns.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Source: PubMed